Research programme: IGF1 receptor monoconal antibodies - Viridian Therapeutics/Zenas BioPharma
Latest Information Update: 29 May 2021
At a glance
- Originator Viridian Therapeutics
- Developer Viridian Therapeutics; Zenas BioPharma
- Class Eye disorder therapies; Monoclonal antibodies
- Mechanism of Action IGF type 1 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Graves ophthalmopathy